



18 January 2023

Non-Renounceable Rights Issue Extension of Closing Date

Opyl Limited (ASX:OPL) (Company) advises that it has resolved to extend the Closing Date of its Non-Renounceable Rights Issue by two (2) weeks to 5.00pm (AEDT) Monday, 13 February 2023. The decision to extend follows requests by shareholders noting the holiday period to enable additional time to evaluate the opportunity.

On 23 December 2022, the Company announced a pro-rata non-renounceable entitlement issue to eligible shareholders of one (1) New Share for every four (4) existing Shares held by eligible shareholders on the Record Date, an issue price of A\$0.03 per New Share, to raise up to \$480,390 (before costs) (**Rights Issue**).

The Rights Issue is being offered to shareholders with a registered address in Australia or New Zealand as at the Record Date (**Eligible Shareholders**).

The Closing Date for the Offer has been extended by two (2) weeks to 5.00pm (AEDT) Monday, 13 February 2023.

The revised indicative timetable for the Offer is set out below:

Event	
Announcement of Rights Issue Offer	Friday, 23 December 2022
Ex-Date	Friday, 30 December 2022
Record Date (to determine Entitlement of Eligible Shareholders to participate in the Offer)	7:00pm (AEDT) Tuesday, 3 January 2023
Opening Date of Rights Issue Offer - Despatch of the Offer Document and online Entitlement & Acceptance Form to Eligible Shareholders	Wednesday, 4 January 2023
Letter to Ineligible Shareholders	Wednesday, 4 January 2023
Last day to extend the Closing Date	12.00pm (AEDT) Wednesday, 8 February 2023
Closing Date for acceptances under the Rights Issue Offer	5:00pm (AEDT) Monday, 13 February 2023
Shortfall (if any) announced to the ASX	Wednesday, 15 February 2023
Issue of the New Rights Issue Shares	Wednesday, 15 February 2023
Trading (T+2) of New Shares expected to commence	Thursday, 16 February 2023

* The Directors may extend the Closing Date by giving at least 3 Business Days' notice to ASX prior to the Closing Date. Accordingly, the date the Securities are expected to commence trading on ASX may vary.

** These dates are indicative only and are subject to change.



Eligible Shareholders will need to ensure their application moneys for their entitlements and any Shortfall Securities (as defined in the Offer Document) are received by Automic Group Pty Limited no later than 5.00pm (AEDT) on Monday, 13 February 2023.

The Offer Document for the Rights Issue has been despatched to Eligible Shareholders and is available on the ASX website and via the Opyl website. Eligible Shareholders should read the Offer Document.

Applications for New Shares by Eligible Shareholders can only be made on an online original Entitlement & Acceptance Form sent with this Offer Document (or payment via BPAY®, as described herein). The online Entitlement & Acceptance Form sets out an Eligible Shareholder's Entitlement to participate in the Offer that is accessible via the Offer Website:

<https://investor.automic.com.au/#/home>

Shareholders (other than the Directors and related parties of the Company) may subscribe for Additional Shares beyond their entitlement of 1 for 4 on the basis that some existing Shareholders may fail to fully take up their Entitlement. This additional ability is available only to eligible holders and is referred to as a Top-Up Facility.

If there remains any Shortfall after allocation of the Additional Shares, the Directors reserve the right for up to 3 months after the close of the Offer to place any Shortfall to wholesale or exempt investors at the Board's discretion but at a price no less than the Offer Price.

The Board has authorised this announcement for release to the ASX.

- ENDS-

For media and investor enquiries: info@opyl.ai

For clinical trial recruitment enquiries: info@opin.ai

www.opyl.ai

www.opin.ai

Opyl is a new generation Australian digital health company that applies artificial intelligence to improving clinical trials. Our platforms make clinical trials more efficient and easier to access, giving patients more options and saving medical researchers time and money.

Our key offering for biopharma, medtech, government and healthcare organisations:

- clinical trial recruitment solutions – Opin.ai
- clinical trial predictive analytics and protocol design – TrialKey
- deep social media insights and analysis – Social Insights

Follow Opyl on Twitter (@Opylai), LinkedIn and Facebook